Summary
A 42-year-old mechanic for a government contractor was denied a security clearance due to concerns under Guideline H (Drug Involvement and Substance Misuse) and Guideline E (Personal Conduct). The applicant admitted to using marijuana from 1993 to the present, including after receiving a security clearance in June 2006. This long-term drug use, particularly after obtaining a clearance, raised initial concerns.
Further issues arose from the applicant's personal conduct. On March 3, 2016, the applicant falsified his e-QIP by denying his drug use. This act of dishonesty was cited as questionable judgment and a direct misrepresentation, triggering disqualifying conditions related to both drug involvement and personal conduct.
The judge determined that the applicant's admitted long-term marijuana use and the falsification of his e-QIP demonstrated a lack of candor, reliability, and trustworthiness. No evidence was presented to mitigate these concerns, leading to the denial of the security clearance.
Why the Applicant Was Denied
- Applicant admitted to long-term marijuana use, including use after obtaining a security clearance.
- Applicant falsified his e-QIP by denying drug use, raising questions about his honesty and reliability.
- No evidence was presented to mitigate the concerns regarding drug involvement or personal conduct.
Conditions Referenced
- H.25(a)appliedAny Substance Misuse
- H.25(f)appliedAny Illegal Drug Use While Granted Access to Classified Information or Holding a Sensitive Position
- E.16(a)appliedDeliberate Omission, Concealment, or Falsification of Relevant Facts
- E.16(e)appliedPersonal Conduct That Creates a Vulnerability to Exploitation
Key Rule Quoted
“The protection of the national security is the paramount consideration.”
Procedural Posture
- SOR issuedMay 26, 2017
- Answer filedJul 5, 2017
- Hearing heldOct 4, 2017via video teleconference
- Decision dateApr 23, 2018
Cite For
- Denial of Security Clearance Due to Long-term Drug Involvement
- Falsification of E-qip as a Disqualifying Factor
- Lack of Mitigating Evidence for Drug-related Concerns